3次元培養を用いた甲状腺眼症における眼窩部炎症線維化の病態解明

Research Project

Project/Area Number	21K16900
Research Category	Grant-in-Aid for Early-Career Scientists
Allocation Type	Multi-year Fund
Review Section	Basic Section 56060:Ophthalmology-related
Research Institution	Sapporo Medical University
Principal Investigator	日景史人札幌医科大学, 医学部, 講師 (30837547)
Project Period (FY)	2021-04-01 – 2026-03-31
Project Status	Granted (Fiscal Year 2021)
Budget Amount *help	¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000) Fiscal Year 2025: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000) Fiscal Year 2024: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000) Fiscal Year 2023: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000) Fiscal Year 2022: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2021: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords	甲状腺眼症 / ３次元培養 / IGF-1 / TSH / HIF2A
Outline of Research at the Start	甲状腺眼症（thyroid-associated ophthalmopathy: TAO）におけるTSHレセプターおよびIGF-1レセプターと低酸素誘導因子2A（Hypoxia inducible factor 2A: HIF2A）との関係性を眼窩部線維芽細胞の3次元培養を用いて解析し、新たな治療薬となり得るHIF2Aアンタゴニストやリシルオキシダーゼ（Lysyl oxidase: LOX）アンタゴニストの有効性を検討する。